Methods of tumor vaccination
AssigneeDcprime B.V.
InventorsErik Hans MANTING, Satwinder Kaur SINGH, Vinod SOMMANDAS
Life of this patent
Estimating the term…
Abstract
A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.
Claims30
1-74. (canceled)
A method for generating an immune response against a tumor in a subject comprising:
- a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof;
- and
- a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof.
(canceled)
82-86. (canceled)
(canceled)
90-91. (canceled)
(canceled)
97-98. (canceled)
101-105. (canceled)
107-108. (canceled)
111-113. (canceled)
A method for generating an immune response against a tumor in a subject, comprising administering to the subject a diphtheria toxin or detoxified variant thereof or a nucleic acid encoding the diphtheria toxin or detoxified variant thereof at a tumor site, wherein the subject is previously vaccinated with the diphtheria toxin or detoxified variant thereof or the nucleic acid encoding the diphtheria toxin or detoxified variant thereof.
A method for generating an immune response against a tumor in a subject comprising:
- a vaccination step comprising administering a first composition to the subject at a site distal to a tumor site, wherein the first composition comprises CRM197 or a nucleic acid encoding CRM197;
- and
- a tumor-marking step comprising administering a second composition to the subject at the tumor site, wherein the second composition comprises CRM197 or a nucleic acid encoding CRM197.
Dependencies are inferred from the claim text.